Effect of difelikefalin, a selective kappa opioid receptor agonist, on respiratory depression: A randomized, double‐blind, placebo‐controlled trial

• Autori principali: Eugene R. Viscusi (Autore), Marc C. Torjman (Autore), Catherine L. Munera (Autore), Joseph W. Stauffer (Autore), Beatrice S. Setnik (Autore), Sukirti N. Bagal (Autore)
• Natura: Libro
• Pubblicazione: Wiley, 2021-09-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Abstract Difelikefalin, a selective kappa opioid receptor agonist designed to limit central nervous system (CNS) penetration, is under development for the treatment of pruritus. Its hydrophilic, small‐peptidic structure limits CNS entry, minimizing potential CNS‐mediated adverse events (AEs). This s...